ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002
27. August 2021 07:00 ET
|
ImmunoBrain Checkpoint
ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002 NEW YORK, Friday August 27, 2021 – ImmunoBrain Checkpoint Inc....
ImmunoBrain Checkpoint awarded Alzheimer’s Association grant to support Phase I trial investigating novel immunotherapeutic approach to treat Alzheimer’s disease
01. September 2020 07:06 ET
|
ImmunoBrain Checkpoint
ImmunoBrain Checkpoint awarded Alzheimer’s Association grant to support Phase I trial investigating novel immunotherapeutic approach to treat Alzheimer’s disease NEW YORK, Tuesday September 1, 2020...